Loading
Melanoma oncologist who led the tebentafusp programme in the United States and defined targeted therapy for rare melanoma subtypes.
Richard Carvajal co-led the tebentafusp development programme including the pivotal IMCgp100-202 trial in metastatic uveal melanoma and the early trials of MEK inhibition in uveal melanoma, and led studies of imatinib in KIT-mutant melanoma. He directs medical oncology at Northwell and continues to focus on rare melanoma subtypes.
Shares gp100 (PMEL), IMCgp100-202, Tebentafusp, Uveal melanoma and the tag uveal-melanoma.
Shares IMCgp100-202, Tebentafusp, Uveal melanoma, Melanoma.
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.
Shares Tebentafusp, Uveal melanoma, Melanoma.
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.
Shares Uveal melanoma, Melanoma.
Shares Uveal melanoma, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/